YHYaoming He

Yaoming He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaoming He has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    OSBPL3 regulates colorectal cancer progression by modulating gut microbiota and tumor immune microenvironment

    by Chengxing Wang, Weijun Liang, Jietao Zhong, Jianchang Wei, Chaorong Zhou, Changyi Ma, Yuehua Liao, Yuan Gao, Canxiu He, Yongfeng Ma, et al.

  • Inhibition effects and mechanisms of three curcuminoids against α-glucosidase

    by Xiaofeng Min, Qingqing Yu, Yaxin Wen, Yaoming He, Jinglin Zhao, Xuetao Xu


  • Naringenin suppresses colorectal Cancer progression by targeting the Gankyrin/PI3K /AKT/GSK-3β/β-catenin signaling Axis

    by Chengxing Wang, Weixing Lin, Chunbo Wu, Chaorong Zhou, Yuan Gao, Yongfeng Ma, Canxiu He, Jianchang Wei, Lianmei Li, Rihui Wu, et al.

    Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide. Natural products derived from Traditional Chinese Medicine (TCM), offer promising therapeutic potential due to their multitarget effects and low toxicity. Naringenin (NAR), a major flavonoid found in citrus peel (chenpi), has shown anticancer activity in several tumor types; however, its mechanism in CRC remains incompletely understood. We combined network pharmacology, molecular docking, and experimental validation to explore the anti-CRC mechanisms of NAR. Bioinformatics databases were used to identify overlapping targets between NAR and CRC. Enrichment analyses and protein-protein interaction (PPI) networks were performed. The interaction between NAR and core targets was confirmed via molecular docking. In vitro assays (CCK-8, colony formation, flow cytometry, Transwell) and Western blotting were used to assess the functional and molecular effects of NAR and Gankyrin modulation. In vivo efficacy and toxicity were evaluated using a CRC xenograft model in nude mice. Network pharmacology identified AKT1 as a hub target, and pathway enrichment highlighted PI3K–AKT signalling. Naringenin (NAR) dose-dependently suppressed colorectal cancer (CRC) cell proliferation, migration and invasion, while promoting apoptosis. In vivo, NAR significantly inhibited tumour growth without overt systemic toxicity. Mechanistically, NAR attenuated the Gankyrin–PI3K–AKT–GSK-3β–β-catenin axis. In gain-of-function rescue experiments, Gankyrin overexpression partially blunted the anti-proliferative and anti-invasive effects of NAR, supporting a Gankyrin-dependent component of NAR activity. This study reveals that NAR exerts anti-CRC effects by targeting the Gankyrin/ PI3K/AKT/GSK-3β/β-catenin pathway, supporting its potential as a safe and effective therapeutic agent in CRC treatment.


  • Targeting the USP7-PGAM5 axis overcomes oxaliplatin resistance in colorectal cancer

    by Chengxing Wang, Canxiu He, Yongfeng Ma, Weijun Liang, Chaorong Zhou, Jinglin Zhao, Yaoming He

  • Open Access

    Implementing bilingual education in gastrointestinal surgery: theory, practice, and insights from China

    by Chengxing Wang, Chaorong Zhou, Yongfeng Ma, Canxiu He, Jinglin Zhao, Yaoming He

    This study aims to evaluate the effectiveness of a structured Chinese–English bilingual teaching model in the context of gastrointestinal surgery edu


  • m6A-mediated regulation of CPSF6 by METTL3 promotes oxaliplatin resistance in colorectal cancer through enhanced glycolysis

    by Chengxing Wang, Weijun Liang, Jietao Zhong, Jiachen Liu, Chaorong Zhou, Changyi Ma, Yuehua Liao, Yuan Gao, Jinglin Zhao, Yaoming He


  • Open Access

    Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma

    by Chengxing Wang, Zhenyu Zhao, Yuhao Zhang, Weijun Liang, Chaorong Zhou, Weixing Lin, Yu He, Meimei Wu, Zijie Meng, Yuehua Liao, et al.

    CUL7, a gene composed of 26 exons associated with cullin 7 protein, is also an E3 ligase that is closely related to cell senescence, apoptosis, and cell transformation and also plays an important role in human cancer. However, there is no systematic pan-cancer analysis has been performed to explore its role in prognosis and immune prediction. In this study, the expression of CUL7 in colon adenocarcinoma (COAD) was investigated to determine its prognosis value. First, based on the Cancer Genome Atlas (TCGA), Genotypic-Tissue Expression Project(GTEx), Cancer Cell Line Encyclopedias(CCLE), and TISIDB database, the potential role of CUL7 in different tumors was explored. Subsequently, the expression of CUL7 in COAD was explored and verified by Immunohistochemistry (IHC). Furthermore, the mutation frequency of CUL7 in COAD was analyzed, and the prognostic value of CUL7 in COAD was discussed. In addition, the nomogram was constructed, and its prognostic value was verified by follow-up data from Jiangmen Central Hospital. Finally, PPI network analysis explored the potential biological function of CUL7 in COAD. The results show that CUL7 is upregulated in most tumors, which is significantly associated with poor survival. At the same time, CUL7 is correlated with the clinical stage and immune landscape of various tumors. In colorectal cancer, CUL7 was overexpressed in tumor tissues by IHC with a mutation frequency of about 4%. CUL7 is an independent prognostic factor for colorectal cancer. The nomogram constructed has effective predictive performance, and external databases proved the prognostic value of CUL7. In addition, PPI network analysis showed that CUL7 was closely related to FBXW8, and further pathway enrichment analysis showed that CUL7 was mainly involved in ubiquitin-mediated proteolysis. Therefore, our study provides a comprehensive understanding of the potential role of CUL7 in different tumors, and CUL7 might be a prognostic marker for COAD.


  • Open Access

    Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10

    by Chengxing Wang, Bin Wang, Weijun Liang, Chaorong Zhou, Weixing Lin, Zijie Meng, Wanting Wu, Meimei Wu, Yuehua Liao, Xiaoping Li, et al.

    Background: Lymph node metastasis (LNM) is a critical event during the colorectal cancer (CRC) development and is indicative of poor prognosis. Identification of molecular markers of LNM may facilitate better therapeutic decision-making.Methods: Six pairs of CRC tissues and corresponding adjacent tissues [3 pairs diagnosed as pT1N0M0 (M_Low group) and 3 pairs diagnosed as pT4N2M0 (M_High group)] collected from CRC patients who underwent surgical resection were used. MicroRNA sequencing was performed to screen differential microRNAs involved in CRC LNM. The selected microRNAs were validated in CRC tissues and cell lines using qRT-PCR. The functions of candidate hsa-miR-1248 were evaluated by CCK-8, colony formation, and Transwell assay. The binding of hsa-miR-1248 with its target PSMD10 was confirmed by luciferase activity assay, and the expression of PSMD10 in tissues was detected by droplet digital polymerase chain reaction.Results: Ninety-five miRNAs were downregulated in carcinoma tissues (M_Low and M_high groups) compared with the normal group. Their expression in M_High group was significantly lower compared with M_Low group. The top 3 were hsa-miR-635, hsa-miR-1248, and hsa-miR-668-3p. After validation in tissues/cell lines, only hsa- hsa-miR-1248 was decreased in high metastatic tissues or SW620 cells compared to low metastatic tissues or SW480 cells. Hsa-miR-1248 was found to inhibit CRC cell viability, proliferation, invasion, and migration. The tumor suppressor effect of has-miR-1248 in CRC cells was attenuated or enhanced by up-regulating or down-regulating PSMD10, respectively.Conclusion: Hsa-miR-1248 may act as a tumor suppressor gene in CRC by targeting and inhibiting PSMD10, which provides a clue for CRC treatment.


  • Open Access

    Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10

    by Chengxing Wang, Bin Wang, Weijun Liang, Chaorong Zhou, Weixing Lin, Zijie Meng, Wanting Wu, Meimei Wu, Yuehua Liao, Xiaoping Li, et al.

    Background. Lymph node metastasis (LNM) is a critical event during the colorectal cancer (CRC) development and is indicative of poor prognosis. Identification of molecular markers of LNM may facilitate better therapeutic decision-making. Methods. Six pairs of CRC tissues and corresponding adjacent tissues [3 pairs diagnosed as pT1N0M0 (M_Low group) and 3 pairs diagnosed as pT4N2M0 (M_High group)] collected from CRC patients who underwent surgical resection were used. MicroRNA sequencing was performed to screen differential microRNAs involved in CRC LNM. The selected microRNAs were validated in CRC tissue and cell lines using qRT-PCR. The functions of candidate miR-1248 were evaluated by CCK-8, colony formation, and Transwell assay. The binding of miR-1248 with its target PSMD10 was confirmed by luciferase activity assay, and the expression of PSMD10 in tissues was detected by droplet digital polymerase chain reaction. Results. Ninety-five miRNAs were downregulated in carcinoma tissue (M_Low and M_high groups) compared with Normal group. Their expression in M_High group was significantly lower compared with M_Low group. The top3 were hsa-miR-635, hsa-miR-1248, and hsa-miR-668-3p. After validation in tissues/cell lines, only hsa-miR-1248 was decreased in high metastatic tissues or SW620 cells compared to low metastatic tissues or SW480 cells. hsa-miR-1248 was found to inhibit CRC cell viability, proliferation, invasion, and migration. The tumor suppressor effect of miR-1248 in CRC cells was attenuated or enhanced by up-regulating or down-regulating PSMD10, respectively. Conclusion. miR-1248 may act as a tumor suppressor gene in CRC by targeting and inhibiting PSMD10, which provides a clue for CRC treatment.

  • Open Access

    Gankyrin as Potential Biomarker for Colorectal Cancer With Occult Liver Metastases

    by Chengxing Wang, Xiaoping Li, Liangliang Ren, Changyi Ma, Meimei Wu, Weijun Liang, Jinglin Zhao, Shangren Li, Qunying Tan, Yuehua Liao, et al.

    The majority of occult liver metastases cannot be detected by computed tomography (CT), magnetic resonance imaging (MRI) or other traditionally morphological imaging approaches since the lesions are too small or they have not yet formed cancer nodules. Gankyrin is a small molecular protein composed of seven ankyrin domains. In this study, the expression of Gankyrin in colorectal cancer (CRC) patients with liver metastases was investigated to determine its prognosis value. Gankyrin expression in CRC patients was initially analyzed using data from The Cancer Genome Atlas (TCGA) database and bioinformatics tools. RT-qPCR, western blotting, immunohistochemistry (IHC) and transwell migration and invasion assays were then performed to verify the expression and function of Gankyrin in CRC cell line, CRC tissues and matched non-tumor tissues of clinical patients. General clinicopathological information including TNM stage as well as preoperative and postoperative imaging results were collected. The main outcome indicator was overall survival (OS), referring to the length of time from surgery to either death or the last visit. Statistical analyses included chi-squared tests, Cox analyses, progression free survival (PFS) rates and OS rates. Elevated Gankyrin expression was confirmed in CRC patients. The upregulated Gankyrin expression was positively correlated with the progression of disease and liver metastasis in CRC patients. OS analysis revealed that prognosis was worse in CRC patients with high Gankyrin expression compared to those with low expression. CRC patients with higher Gankyrin expression also had a higher risk of occult liver metastases and a lower PFS rate. Therefore, Gankyrin can be used as a potential biomarker for early diagnosis of CRC with occult liver metastasis.